Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.

MLA

Kato, Yasuhiro, et al. “Induction of Resistance to Neurotrophic Tropomyosin‐receptor Kinase Inhibitors by HMGCS2 via a Mevalonate Pathway.” Cancer Medicine, vol. 13, no. 12, June 2024, pp. 1–14. EBSCOhost, https://doi.org/10.1002/cam4.7393.

APA

Kato, Y., Matsumoto, M., Takano, N., Hirao, M., Matsuda, K., Tozuka, T., Onda, N., Nakamichi, S., Takeuchi, S., Miyanaga, A., Noro, R., Gemma, A., & Seike, M. (2024). Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway. Cancer Medicine, 13(12), 1–14. https://doi.org/10.1002/cam4.7393

Chicago

Kato, Yasuhiro, Masaru Matsumoto, Natsuki Takano, Mariko Hirao, Kuniko Matsuda, Takehiro Tozuka, Naomi Onda, et al. 2024. “Induction of Resistance to Neurotrophic Tropomyosin‐receptor Kinase Inhibitors by HMGCS2 via a Mevalonate Pathway.” Cancer Medicine 13 (12): 1–14. doi:10.1002/cam4.7393.